Amira A Zidan, Ahmed Yousef Jad, Nermine H Zakaria, Hazem M El-Hariri, Maged El-Setouhy
{"title":"Assessment of the factors affecting the clinical outcomes of infection and safety of vaccines against SARS-CoV-2 among Egyptian patients.","authors":"Amira A Zidan, Ahmed Yousef Jad, Nermine H Zakaria, Hazem M El-Hariri, Maged El-Setouhy","doi":"10.1186/s12879-024-10362-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Understanding the factors that influence clinical outcomes of COVID-19 and the safety of various vaccines is important to inform public health strategies, particularly in diverse communities. This study aimed to assess the factors affecting the clinical outcomes of COVID-19 and vaccination safety among the Egyptian population.</p><p><strong>Methods: </strong>In a retrospective study, we examined 1597 patients who tested positive for COVID-19. Among them, 1280 patients had received the vaccination, while 317 patients had not. We collected data from medical records, which included clinical characteristics, comorbidities, disease severity, type of vaccination, and adverse hematological effects postvaccination. We calculated the relative risk, odds ratio, and 95% confidence intervals (CIs).</p><p><strong>Results: </strong>Among the 1,597 COVID-19 cases, 74.1% were mild, 24.8% were moderate, and 1.1% were severe. Significant factors for moderate/severe cases included male sex (RR 0.78, 95% CI 0.64-0.95), cardiovascular diseases (RR 1.86, 95% CI 1.32-2.64), respiratory diseases (RR 1.40, 95% CI 1.08-1.82), diabetes mellitus (RR 1.41, 95% CI 1.07-1.86), and previous COVID-19 infection (RR 1.22, 95% CI 1.02-1.46). Vaccination reduced the severity risk, with BBIBP-CorV (Sinopharm) showing a significant protective effect (OR 0.78, 95% CI 0.62-0.98). Clinical presentations varied, with 97.6% having an oxygen saturation ≥ 92%. Logistic regression indicated that male sex and BBIBP-CorV (Sinopharm) vaccination were protective factors. Linear regression revealed that the male sex increased hemoglobin and leucocyte counts, whereas BBIBP-CorV (Sinopharm) decreased leucocyte and platelet counts.</p><p><strong>Conclusion: </strong>Vaccination, particularly with BBIBP-CorV (Sinopharm), significantly reduces COVID-19 severity among Egyptians, despite various clinical presentations and hematological effects.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"384"},"PeriodicalIF":3.0000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924763/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12879-024-10362-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Understanding the factors that influence clinical outcomes of COVID-19 and the safety of various vaccines is important to inform public health strategies, particularly in diverse communities. This study aimed to assess the factors affecting the clinical outcomes of COVID-19 and vaccination safety among the Egyptian population.
Methods: In a retrospective study, we examined 1597 patients who tested positive for COVID-19. Among them, 1280 patients had received the vaccination, while 317 patients had not. We collected data from medical records, which included clinical characteristics, comorbidities, disease severity, type of vaccination, and adverse hematological effects postvaccination. We calculated the relative risk, odds ratio, and 95% confidence intervals (CIs).
Results: Among the 1,597 COVID-19 cases, 74.1% were mild, 24.8% were moderate, and 1.1% were severe. Significant factors for moderate/severe cases included male sex (RR 0.78, 95% CI 0.64-0.95), cardiovascular diseases (RR 1.86, 95% CI 1.32-2.64), respiratory diseases (RR 1.40, 95% CI 1.08-1.82), diabetes mellitus (RR 1.41, 95% CI 1.07-1.86), and previous COVID-19 infection (RR 1.22, 95% CI 1.02-1.46). Vaccination reduced the severity risk, with BBIBP-CorV (Sinopharm) showing a significant protective effect (OR 0.78, 95% CI 0.62-0.98). Clinical presentations varied, with 97.6% having an oxygen saturation ≥ 92%. Logistic regression indicated that male sex and BBIBP-CorV (Sinopharm) vaccination were protective factors. Linear regression revealed that the male sex increased hemoglobin and leucocyte counts, whereas BBIBP-CorV (Sinopharm) decreased leucocyte and platelet counts.
Conclusion: Vaccination, particularly with BBIBP-CorV (Sinopharm), significantly reduces COVID-19 severity among Egyptians, despite various clinical presentations and hematological effects.
背景：了解影响COVID-19临床结局和各种疫苗安全性的因素对于制定公共卫生战略非常重要，特别是在不同社区。本研究旨在评估影响埃及人群COVID-19临床结局和疫苗接种安全性的因素。方法：在一项回顾性研究中，我们检查了1597例COVID-19检测阳性的患者。其中接种1280例，未接种317例。我们从医疗记录中收集数据，包括临床特征、合并症、疾病严重程度、疫苗接种类型和疫苗接种后的不良血液学反应。我们计算了相对危险度、优势比和95%置信区间（ci）。结果：1597例新冠肺炎病例中，轻症74.1%，中度24.8%，重度1.1%。中/重度病例的显著因素包括男性（RR 0.78, 95% CI 0.64-0.95）、心血管疾病（RR 1.86, 95% CI 1.32-2.64）、呼吸系统疾病（RR 1.40, 95% CI 1.08-1.82）、糖尿病（RR 1.41, 95% CI 1.07-1.86）和既往COVID-19感染（RR 1.22, 95% CI 1.02-1.46）。疫苗接种降低了严重风险，BBIBP-CorV（国药控股）显示出显著的保护作用（OR 0.78, 95% CI 0.62-0.98）。临床表现各不相同，97.6%的患者氧饱和度≥92%。Logistic回归分析显示，男性和接种国药疫苗是保护因素。线性回归显示，男性患者血红蛋白和白细胞计数增加，而BBIBP-CorV（国药）降低白细胞和血小板计数。结论：尽管有不同的临床表现和血液学影响，但接种疫苗，特别是BBIBP-CorV（国药控股）疫苗，可显著降低埃及人的COVID-19严重程度。临床试验号：不适用。
期刊介绍：
BMC Infectious Diseases is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of infectious and sexually transmitted diseases in humans, as well as related molecular genetics, pathophysiology, and epidemiology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
